Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • Usefulness of serial blood sampling and PCR replicates for treatment monitoring of patients with chronic Chagas disease
  • The BMJ special supplement: Innovation for Neglected Diseases in South Asia
  • A randomized trial of AmBisome® monotherapy and AmBisome® and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

RSS PRESS RELEASES

  • Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis
  • Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
  • MMV and DNDi make 400 compounds available to stimulate research into new drugs for pandemic diseases

RSS NEWS

  • Professor Balram Bhargava joins the Board of Directors at DNDi
  • An HIV/VL patient’s long road to better treatment
  • 2018 in Review

RSS IN THE MEDIA

  • Health Policy Watch: “Civil society request fair pricing for medicines, transparency, at WHO”
  • Health Policy Watch: “New funding partnership to develop innovative drugs for leishmaniasis”
  • Agence d’information d’Afrique centrale: “Kinshasa autorise la vente d’un médicament contre la maladie du sommeil”

RSS EVENTS

  • Wellcome Centre for Anti-Infective Research at the University of Dundee
  • XV Chagas disease workshop – ISGlobal
  • 4th National Hepatitis Conference 2019

RSS Scientific Articles

  • Usefulness of serial blood sampling and PCR replicates for treatment monitoring of patients with chronic Chagas disease
  • The BMJ special supplement: Innovation for Neglected Diseases in South Asia
  • A randomized trial of AmBisome® monotherapy and AmBisome® and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
  • Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

Social Mission Ration 2017

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close